Paul D Rubin sold $151k of BIOA
Chief Medical Officer at BioAge Labs, Inc.. 7,433 shares at an average of $20.30, traded Mar 2, 2026, filed Mar 3, 2026.
Score components
- +15RoleOfficer
- +11Trade size$151k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -14.5%, 3m -19.2%, 6m -53.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001210905-26-000009, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | MOption exercise Common Stock10b5-1 | +5,433 | $4.11 | $22k | 5,433 | Mar 3, 2026 |
| Mar 2, 2026 | MOption exercise Common Stock10b5-1 | +2,000 | $6.57 | $13k | 7,433 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -7,433 | $20.30 | $151k | 0 | Mar 3, 2026 |
| Mar 2, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,433 | $0.00 | $0 | 5,437 | Mar 3, 2026 |
| Mar 2, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,000 | $0.00 | $0 | 3,383 | Mar 3, 2026 |
Related signals
Other insiders at BioAge Labs, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | BioAge Labs, Inc. | Shane Barton Principal Accounting Officer | $1.6M 62,566 shares | -148% | |
| 11Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $157k 8,820 shares | -100% | |
| 11Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $139k 7,433 shares | -100% | |
| 40Moderate | BioAge Labs, Inc. | Dov A Goldstein Md Chief Financial Officer | $532k 27,000 shares | -55% | |
| 50Moderate | BioAge Labs, Inc. | Kristen Fortney Chief Executive Officer | $4.2M 233,107 shares | -19% | |
| 25Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $95k 7,433 shares | -100% | |
| 12Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $216k 18,000 shares | -100% | |
| 21Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $702k 68,897 shares | -100% | |
| 29Weak | BIOAbuy BioAge Labs, Inc. | Shane Barton Principal Accounting Officer | $47k 2,632 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.